IRIS UniCatt

Ciccullo, Arturo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.200
AS - Asia 813
EU - Europa 704
SA - Sud America 199
AF - Africa 32
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.954
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.153
SG - Singapore 371
SE - Svezia 212
CN - Cina 202
BR - Brasile 173
IT - Italia 118
DE - Germania 103
FR - Francia 85
IN - India 65
VN - Vietnam 48
IE - Irlanda 44
ID - Indonesia 32
GB - Regno Unito 29
CA - Canada 27
FI - Finlandia 24
RU - Federazione Russa 19
JP - Giappone 15
PL - Polonia 15
BD - Bangladesh 13
MX - Messico 13
AR - Argentina 12
TR - Turchia 12
ES - Italia 11
BE - Belgio 10
IQ - Iraq 10
ZA - Sudafrica 10
KR - Corea 8
NL - Olanda 8
UA - Ucraina 8
HK - Hong Kong 6
EC - Ecuador 5
LT - Lituania 5
CH - Svizzera 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
AT - Austria 3
IR - Iran 3
JO - Giordania 3
KE - Kenya 3
TN - Tunisia 3
TW - Taiwan 3
AU - Australia 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
EG - Egitto 2
EU - Europa 2
JM - Giamaica 2
NZ - Nuova Zelanda 2
PE - Perù 2
PK - Pakistan 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
UZ - Uzbekistan 2
YE - Yemen 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CM - Camerun 1
CR - Costa Rica 1
GT - Guatemala 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
TG - Togo 1
UY - Uruguay 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 2.954
Salva come PNG Salva come JPEG
Città #
Chandler 314
Singapore 167
Ashburn 116
New York 82
Beijing 68
Dublin 44
San Mateo 36
Boston 29
Jakarta 28
Princeton 28
Rome 28
Wilmington 27
Los Angeles 26
Munich 21
Nanjing 21
São Paulo 20
Ho Chi Minh City 19
Dearborn 17
Marseille 17
Redwood City 16
Cattolica 14
Tokyo 14
Frankfurt am Main 13
Helsinki 13
Milan 13
Chicago 12
Brussels 10
Hefei 10
London 10
Montreal 10
Moscow 10
The Dalles 10
Warsaw 10
Santa Clara 9
Turku 9
Atlanta 8
Brooklyn 8
Dallas 8
Fairfield 8
Pune 8
Stockholm 8
Toronto 8
Changsha 7
Nuremberg 7
Guangzhou 6
Jacksonville 6
Johannesburg 6
Mexico City 6
Seattle 6
Shenyang 6
Belo Horizonte 5
Campinas 5
Dhaka 5
Hangzhou 5
Hanoi 5
Hong Kong 5
Houston 5
Jinan 5
Nanchang 5
Querétaro 5
Ankara 4
Bexley 4
Buffalo 4
Busto Arsizio 4
Falkenstein 4
Jiaxing 4
Mumbai 4
Orem 4
Ottawa 4
Paris 4
Philadelphia 4
San Francisco 4
Seoul 4
Tianjin 4
Zurich 4
Alcalá de Henares 3
Amman 3
Ann Arbor 3
Augusta 3
Baghdad 3
Belford Roxo 3
Cleveland 3
Da Nang 3
Hyderabad 3
Kunming 3
Leawood 3
Ribeirão Preto 3
Roubaix 3
Vancouver 3
Vienna 3
Woodbridge 3
Abidjan 2
Amsterdam 2
Ardabil 2
Atibaia 2
Baltimore 2
Bauru 2
Belém 2
Buenos Aires 2
Busan 2
Totale 1.573
Salva come PNG Salva come JPEG
Nome #
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 145
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 136
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 128
Shall we dance? Extending tango's results to clinical practice 125
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 124
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 123
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 122
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 122
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 117
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 112
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 109
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 108
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 107
Dolutegravir plus lamivudine for the treatment of HIV-1 infection 105
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 104
Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study 103
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 103
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 100
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice 100
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 90
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 87
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 87
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients 87
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 86
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 85
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 80
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 75
Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection 73
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 71
Totale 3.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 4 4 2 6 26 31 9
2021/2022282 29 2 7 46 9 5 5 42 6 22 37 72
2022/2023684 102 96 63 106 39 71 33 57 78 2 25 12
2023/2024308 14 78 6 35 6 93 15 1 4 11 17 28
2024/2025526 13 11 41 30 71 24 25 26 63 39 93 90
2025/2026816 187 26 70 198 299 36 0 0 0 0 0 0
Totale 3.014